Browse drugs

… therapeutic positioning.Aim and Objectives To evaluate whether pembrolizumab, dostarlimab, durvalumab, durvalumab plus olaparib, and atezoli…

…umab) are often used in ovarian and cervical cancers. ICIs (eg, pembrolizumab) are effective in mismatch repair-deficient endometrial cancer …

…ion and potential as a therapeutic focus.Methods The potency of AVA-NP-695, a small-molecule ENPP1 inhibitor, was validated through enzyma…

…uppression of TRAMP-C2 and RM-1 tumors compared to mSTAR1302 or Olaparib monotherapies. In both models, combination therapy resulted in …

…ate cancer.Methods The antitumor activity of the PARP inhibitor olaparib combined with mSTAR1302, the murine surrogate of STAR0602, was …

…in the UK due to insufficient evidence.The protective effect of aspirin in reducing colorectal cancer risk among individuals with Lynch…

… inhibitor olaparib in combination with the anti-PD-L1 antibody durvalumab in an HRR-unselected population of men with metastatic castrati…

…erapy –specifically those including pembrolizumab, dostarlimab, durvalumab, durvalumab plus olaparib, and atezolizumab–, in the treatment …

… S, Wong A, Yong WP, Soo RA, Chee CE, Tan DS. 458MO Efficacy of durvalumab (Durva) in combination with olaparib (Ola) and capivasertib (Ca…

…), atezolizumab (Tecentriq), osimertinib (Tagrisso), ceritinib (Zykadia) and nintedanib (Vargatef). EMA labels for all products include…

…ed antitumor immunity in combination-treated tumors.Conclusions Telmisartan depletes tumor PD-L1 but has significant PD-L1-independent clin…

…Results Of 88 patients (mean age 76.9 ± 8.2 years), 70 received abiraterone, 8 apalutamide, six enzalutamide, three darolutamide, and one o…